RxDoctor Payments Data

William Hahn

Medical Oncology · Boston, MANPI 1457313652

Payments from drug & device makers

$922,215in general payments, 2019–2025

Across 39 payments — averaging $23,647 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$527K
  • Eli Lilly$300K
  • Jubilant Therapeutics Inc$81K
  • Genentech, Inc.$8K
  • Sanofi-aventis U.S. LLC$4K
  • Merck$2K
  • plus $250 from 1 others
$42,275in research payments, 2019–2025

Across 37 payments — averaging $1142.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$35K
  • Tesaro, Inc.$6K
  • GSK$1K

What the payments were for

  • Consulting fees$14,09415%
  • Speaking & faculty fees$80,01283%
  • Travel & lodging$2,7693%
  • Food & beverage$900%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer15$526,600
Eli Lilly2$300,000
Jubilant Therapeutics Inc11$80,898
Genentech, Inc.5$8,500
Sanofi-aventis U.S. LLC2$3,568
Merck2$2,400
GSK2$250

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$922,215 in reported general payments places this provider in the 75th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts

Other medical oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →